Ovarian Cancer Clinical Trials in New York, New York

46 studies are recruiting for ovarian cancer in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

   This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mount Sinai Tisch Cancer Center, New York, New York

   Locations

   17 in total

   Run by

   LigaChem Biosciences, Inc.

   See if you can join NCT06774963 on ClinicalTrials.gov

2. Lead-212 PSV359 Therapy for Patients With Solid Tumors

   Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

   Stage

   Phase 1

   Ages

   18 to 90

   Site

   Memorial Sloan Kettering Cancer Center - Main Campus, New York, New York

   Locations

   16 in total

   Run by

   Perspective Therapeutics

   See if you can join NCT06710756 on ClinicalTrials.gov

3. Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

   This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-g…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

   Locations

   232 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06819007 on ClinicalTrials.gov

4. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

   Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   NYU Langone Medical Center, New York, New York

   Locations

   16 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT04981119 on ClinicalTrials.gov

5. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

   This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan-Kettering Cancer Center, New York, New York

   Locations

   88 in total

   Run by

   Artios Pharma Ltd

   See if you can join NCT04657068 on ClinicalTrials.gov

6. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York, New York

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

7. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

   Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   New York Cancer & Blood Specialists, New York, New York

   Locations

   11 in total

   Run by

   Nammi Therapeutics Inc

   See if you can join NCT06582017 on ClinicalTrials.gov

8. Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

   This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence

   Stage

   Not phased

   Ages

   18 and older

   Site

   Mount Sinai Health System, New York, New York

   Locations

   11 in total

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05287451 on ClinicalTrials.gov

9. EHR Intervention to Increase HBOC Genetic Testing

   The purpose of this research study is to test how well a new approach - using tools built into the electronic health record (EHR)- can help increase genetic testing for hereditary breast and ovarian cancer (HBOC) in women who have a family history that puts them at higher risk. The study will also …

   Stage

   Not phased

   Ages

   21 to 75

   Site

   Columbia University Irving Medical Center, New York, New York

   Run by

   Columbia University

   See if you can join NCT07876349 on ClinicalTrials.gov

10. A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

    This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, New York, New York

    Locations

    67 in total

    Run by

    AstraZeneca

    See if you can join NCT05123482 on ClinicalTrials.gov

11. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York

    Locations

    26 in total

    Run by

    SystImmune Inc.

    See if you can join NCT06293898 on ClinicalTrials.gov

12. A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

    The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Laura and Isaac Perlmutter Cancer Center ( Site 0076), New York, New York

    Locations

    198 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06824467 on ClinicalTrials.gov

13. A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

    Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev), or bev alone in part…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Columbia University Medical Center /ID# 277990, New York, New York

    Locations

    86 in total

    Run by

    AbbVie

    See if you can join NCT07059845 on ClinicalTrials.gov

14. A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

    Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is us…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center ( Site 0072), New York, New York

    Locations

    167 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT07318558 on ClinicalTrials.gov

15. Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

    The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.

    Stage

    Phase 1

    Ages

    15 and older

    Site

    Icahn School of Medicine at Mount Sinai, New York, New York

    Locations

    27 in total

    Run by

    Xencor, Inc.

    See if you can join NCT06276491 on ClinicalTrials.gov

16. Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

    Genetic testing is a type of test that detects changes to the genes-the DNA instructions that are passed on from the mother and father. The results of a genetic test can confirm whether the participant has a genetic disorder, which is a disease caused in whole or in part by changes to the genes. Ge…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities), New York, New York

    Locations

    4 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT04751435 on ClinicalTrials.gov

17. Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    4 in total

    Run by

    Imunon

    See if you can join NCT05739981 on ClinicalTrials.gov

18. A Study of PHST001 in Advanced Solid Tumors

    This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advan…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mount Sinai, New York, New York

    Locations

    20 in total

    Run by

    Pheast Therapeutics

    See if you can join NCT06840886 on ClinicalTrials.gov

19. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Memorial Sloan Kettering, New York, New York

    Locations

    76 in total

    Run by

    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

20. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, New York, New York

    Locations

    20 in total

    Run by

    AstraZeneca

    See if you can join NCT05877599 on ClinicalTrials.gov

21. A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

    This study is researching an investigational drug called REGN5668 : * alone or, * combined with cemiplimab (also known as REGN2810) or, * combined with both cemiplimab and fianlimab (also known as REGN3767), or * combined with ubamatamab (also known as REGN4018), with or without sarilumab. The main…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    28 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT04590326 on ClinicalTrials.gov

22. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center Head Neck Services, New York, New York

    Locations

    37 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

23. BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

    The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    25 in total

    Run by

    BioInvent International AB

    See if you can join NCT04752826 on ClinicalTrials.gov

24. A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

    This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

    Stage

    Phase 2

    Ages

    18 to 99

    Site

    Laura and Isaac Perlmutter Cancer Center, New York, New York

    Locations

    74 in total

    Run by

    Incyte Corporation

    See if you can join NCT07023627 on ClinicalTrials.gov

25. A Study of Isoquercetin in People With Ovarian Cancer

    The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York, New York

    Locations

    8 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07303894 on ClinicalTrials.gov